Previous studies have shown that leukemia or lymphoma patients treated with CD19-targeted BITE (blinatumomab) achieved sustained remission [18, 23, 62]; however, repeated injections were necessary due to the short half-life of BITEs in circulation [63]. This evidence concerns the gene CD19 and lymphoma.